×
Zymeworks Income Taxes 2016-2024 | ZYME
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Zymeworks income taxes from 2016 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
View More
Zymeworks Income Taxes 2016-2024 | ZYME
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Zymeworks income taxes from 2016 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$231.2B
Amgen (AMGN)
$160B
Gilead Sciences (GILD)
$137.1B
Vertex Pharmaceuticals (VRTX)
$123.3B
Bristol Myers Squibb (BMY)
$113.2B
CSL (CSLLY)
$80.1B
GSK (GSK)
$76.6B
Regeneron Pharmaceuticals (REGN)
$76.1B
Argenex SE (ARGX)
$39.3B
Alnylam Pharmaceuticals (ALNY)
$32.5B
BioNTech SE (BNTX)
$28.3B
BeiGene (ONC)
$23.9B
Biogen (BIIB)
$20.1B
Illumina (ILMN)
$15.4B
Insmed (INSM)
$15B
Genmab (GMAB)
$14.9B
Genmab (GNMSF)
$14.7B
Incyte (INCY)
$13.8B
Intra-Cellular Therapies (ITCI)
$13.7B
BioMarin Pharmaceutical (BMRN)
$13.1B
Moderna (MRNA)
$13B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Sarepta Therapeutics (SRPT)
$10.4B
Bio-Techne Corp (TECH)
$10.4B
Vaxcyte (PCVX)
$10.3B
Exelixis (EXEL)
$9.8B
Ascendis Pharma (ASND)
$9.4B
Exact Sciences (EXAS)
$9.2B
Repligen (RGEN)
$9.1B
Bio-Rad Laboratories (BIO.B)
$8.7B